Trial Profile
LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Paclitaxel; Vinorelbine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms LUX-Breast-2
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 01 Apr 2022 Results published in the Breast Cancer Research and Treatment
- 22 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 04 Jul 2017 Status changed from active, no longer recruiting to discontinued.